Praxis Precision Medicines
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-09-22
- Employees
- 82
- Market Cap
- $950.3M
- Introduction
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. It is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.
BNP Paribas Financial Markets Has $548,000 Stock Holdings in Praxis Precision Medicines
BNP Paribas Financial Markets increased its stake in Praxis Precision Medicines by 369.4% in Q3, owning 9,525 shares worth $548,000. Other investors also adjusted their positions, with Charles Schwab Investment Management Inc. raising its stake by 188.7% and CIBC Asset Management Inc. by 29.2%. Praxis Precision Medicines has a consensus rating of "Moderate Buy" with a target price of $146.33. Insider sales include General Counsel Alex Nemiroff selling shares valued at $660,767.80.
Praxis Precision Medicines' (PRAX) Buy Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed Praxis Precision Medicines' 'buy' rating with a $120.00 price target, indicating a 59.72% upside potential. Other analysts also raised their price targets and maintained 'buy' or 'outperform' ratings. Praxis stock opened at $75.13 with a market cap of $1.40 billion and a 1-year high of $86.93. The company reported a negative net margin and missed earnings estimates for the quarter.
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
GeneDx partners with Biogen, Praxis Precision Medicines, and Stoke Therapeutics to expand exome testing access for pediatric epilepsy patients, aiming to reduce the diagnostic odyssey and improve treatment outcomes.
Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
GeneDx announces Biogen, Praxis Precision Medicines, and Stoke Therapeutics as founding partners for its Patient Access Program for pediatric epilepsy, aiming to increase access to whole exome sequencing and improve genetic diagnosis rates.
Praxis Precision Medicines to showcase updates from pipeline of epilepsy ...
Praxis Precision Medicines to present preclinical and clinical data on relutrigine, vormatrigine, and elsunersen at AES 2024, targeting CNS disorders and epilepsy.
Praxis Precision Medicines To Showcase Update...
Never miss a trade with the fastest news alerts via Benzinga Pro, used by 10,000+ traders for exclusive market intelligence.
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full
Praxis Precision Medicines to initiate PRAX-114 Phase 2/3 MDD trial in March 2021, with topline data for PRAX-944 Phase 2a high dose cohort expected mid-2021. Collaboration with The Florey Institute adds 3 ASOs for rare epilepsies. Cash balance of $296.6M as of Dec 31, 2020, supports operations into 4Q22.
Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.
Verition Fund Management LLC and Nicholas Maounis report beneficial ownership of 314,294 shares (1.8%) of Praxis Precision Medicines, Inc. common stock, held for Verition Multi-Strategy Master Fund Ltd., with shared voting and dispositive power.
Provides Corporate Update and Reports Third Quarter 2024
Praxis Precision Medicines reports Q3 2024 financial results, with interim analysis for Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025. Registrational Cohort 2 of EMBOLD study recruiting following positive topline results for Cohort 1 in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). Vormatrigine (PRAX-628) on track for topline from POWER1 study in focal epilepsy and RADIANT study in focal and generalized epilepsy in 2025. Praxis maintains runway into 2027.
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
Praxis Precision Medicines to participate in three investor conferences in Nov 2024: Truist Securities BioPharma Symposium, Guggenheim Securities Inaugural Healthcare Innovation Conference, and Jefferies London Healthcare Conference.
© Copyright 2025. All Rights Reserved by MedPath